TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06024408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
Study: NCT05877521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE treatments
Description: MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE treatments
Description: MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE treatments
Description: MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for Pain Management
Description: Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
Study: NCT06517446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Virtual Reality Stimulation
Description: Optokinetic stimulation;~• A warning will be given by colored balloons rotating clockwise and counterclockwise, starting at 10°/second and gradually increasing up to 60°/second. • Optokinetic stimulation will start with 30 seconds and increase to 150 seconds as the sessions progress. • Patients are asked to focus on a balloon in the moving image. • Stimulations will be given when the patient is sitting, in a semi-tandem stance, in a tandem stance, or standing upright.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation program based on Cawthorne Cooksey exercises
Description: The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
Study: NCT06056232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)-normal version
Description: Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance
Description: Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance
Description: Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
Study: NCT05164029

Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.

Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
Study: NCT06154109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaopi granules
Description: Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaopi decoction
Description: Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain any active pharmaceutical ingredients .
Study: NCT05293951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Strengthening Device
Description: Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions.
Study: NCT05062187

Intervention type: OTHER
Intervention: Proprioseption in hemiparetics
Description: Proprioception on balance and gait functions in hemiparetic individuals

Intervention type: OTHER
Intervention: Proprioseption in hemiparetics
Description: Proprioception on balance and gait functions in hemiparetic individuals
Study: NCT04801810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation (experimental).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normobaric normoxia
Description: Normal oxygen exposure to mimic sea level conditions (sham comparator).
Study: NCT06078137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual PROMs and new PROMs strategy
Description: Patients randomized to intervention receive both usual PROMs and new PROMs strategy
Study: NCT05168839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).
Description: In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.
Study: NCT05404828

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI

Intervention type: OTHER
Intervention: Questionnaires
Description: STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36

Intervention type: OTHER
Intervention: Questionnaires
Description: STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36

Intervention type: OTHER
Intervention: Questionnaires
Description: STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36

Intervention type: OTHER
Intervention: Blood and urine sample
Description: Na, K, Creat, Osm, Urea

Intervention type: OTHER
Intervention: Blood and urine sample
Description: Na, K, Creat, Osm, Urea

Intervention type: OTHER
Intervention: Blood and urine sample
Description: Na, K, Creat, Osm, Urea
Study: NCT05101902

Intervention type: OTHER
Intervention: Pre-Screening
Description: No intervention given
Study: NCT05120180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection with vein branches reservation
Description: Spare the vein branches when ALND being performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection without vein branches reservation
Description: Don't spare the vein branches when ALND being performed
Study: NCT05910073

Intervention type: DEVICE
Intervention: Lamina curved plate
Description: Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
Study: NCT06031727

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG202
Description: Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
Study: NCT06322160

Intervention type: OTHER
Intervention: Interview
Description: Interview with individual participant will take place via online videoconferencing MS Teams

Intervention type: OTHER
Intervention: Interview
Description: Interview with individual participant will take place via online videoconferencing MS Teams
Study: NCT03694158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: anti-IL4 receptor antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Dupilumab (packaged/administered the same as the active drug)
Study: NCT05323812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TW001
Description: daily dose of 100 mg TW001/placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily dose of 100 mg TW001/placebo
Study: NCT05569759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zetomipzomib
Description: Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zetomipzomib in open-label extension
Description: Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
Study: NCT06529380

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS ON
Description: Electrical stimulation of the nucleus accumbens.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS ON
Description: Electrical stimulation of the nucleus accumbens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS OFF
Description: DBS will remain OFF (on at 0V).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS OFF
Description: DBS will remain OFF (on at 0V).
Study: NCT05887375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
Study: NCT05400967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Study: NCT06058533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Previsit Imagery Picturebook
Description: This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
Study: NCT06371768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AYA Educational Information
Description: AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions. Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AYA STEPS
Description: The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care. Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques. Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
Study: NCT06536413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose 0
Description: Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose -1
Description: Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose 1
Description: Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Study: NCT05615922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-Naming Activity
Description: During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
Study: NCT06374238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+ Health coach
Description: Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in CBT w/ Health coach group will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. In addition participants will have weekly contact with a peer health coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT w/o Health Coach ( self-guided)
Description: Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants CBT w/o Health coach groups will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in the UC group will be asked to engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
Study: NCT04906668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary-vein isolation
Description: Electrical isolation of the pulmonary-veins using cryoenergy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation and ablation of atrioventricular-node
Description: Pacemaker implantation and ablation of atrioventricular-node